Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO? [electronic resource]
Producer: 19930330Description: 11-8 p. digitalISSN:- 1058-2916
- Anemia -- drug therapy
- Centers for Medicare and Medicaid Services, U.S
- Drug Administration Schedule
- Drug Costs
- Erythropoietin -- administration & dosage
- Hemodialysis Units, Hospital -- economics
- Humans
- Kidney Failure, Chronic -- complications
- Medicare -- economics
- Recombinant Proteins -- administration & dosage
- Reimbursement Mechanisms
- Renal Dialysis -- economics
- United States
- United States Food and Drug Administration
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.